...
首页> 外文期刊>Blood purification >Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients
【24h】

Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients

机译:含有倍转羟基氧化物的慢性疗法不会影响透析患者的熨斗和贫血标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction:Sucroferric oxyhydroxide (SOH) is an iron-based phosphate binder (PB), and its use has been widely expanded since its initial approval in 2014. Based on the existing data, however, it remains yet unclear whether its long-term administration is followed by iron overload in dialysis patients. The purpose of this observational study was to evaluate the longstanding effects of SOH on the anemia and iron indices in patients on dialysis.Methods:A total of 110 patients from 3 dialysis centers were included in the study; 49 were under chronic treatment with SOH (cohort A), while 61 were either receiving other PB or no treatment for hyperphosphatemia (cohort B). We initially compared the hematologic profile of patients in 2 cohorts (phase I), and subsequently, we evaluated modifications of the above parameters in the SOH treated patients over a period of 6 months (phase II).Results:There were no statistically significant differences between 2 cohorts in terms of hemoglobin (Hb; 11.4 +/- 1.3 vs. 11.6 +/- 0.9 g/dL,p= 0.375), ferritin (473 +/- 230 vs. 436 +/- 235 ng/mL,p= 0.419) and transferrin saturation (TSAT;26.6 +/- 13.2 vs. 26.5 +/- 10.6%,p= 0.675), serum phosphate concentration (4.57 +/- 1.05 vs. 4.3 +/- 0.96 mg/dL,p= ns), and intact PTH (286 +/- 313 vs. 239 +/- 296 pg/mL,p= ns). Marginally, but significantly higher calcium levels were found in cohort A compared to cohort B (9.18 +/- 0.58 vs. 8.9 +/- 0.51 mg/dL, respectively,p= 0.008). In phase II, no significant changes were observed in hematological parameters after a 6-month treatment with SOH (Hb: from 11.5 +/- 1.1 to 11.4 +/- 1.3 g/dL,p= 0.4, serum ferritin levels: from 475 +/- 264 to 473 +/- 230 ng/mL,p= 0.951, TSAT: from 26.5 +/- 16.7 to 26.6 +/- 13.2%,p= 0.933). There were also no significant changes in the administration of iron supplements or erythropoietin dose during this period.Conclusions:SOH is an effective PB, and its long-term use is not complicated by iron overload.
机译:介绍:富发羟基氧化物(SOH)是一种铁基磷酸盐粘合剂(Pb),自2014年初步批准以来已广泛扩大。然而,基于现有数据,尚不清楚其长期管理其次是透析患者的铁过载。该观察项研究的目的是评估SOH对透析患者贫血和铁指标的长期影响。方法:研究中共有110名透析中心患者; 49在慢性处理下用SOH(群组A),而61则接受其他Pb或对缓解磷血症(COHORT B)进行治疗。我们最初将患者的血液学剖面与2个群组(I相)进行比较,随后,我们在6个月(II期)的时间内评估了SOH治疗患者的上述参数的修饰。结果:没有统计学上的差异在血红蛋白(Hb; 11.4 +/- 1.3和11.6 +/- 0.9g / dl,p = 0.375),铁蛋白(473 +/- 230与436 +/- 235 ng / ml,p = 0.419)和转铁蛋白饱和度(TSAT; 26.6 +/- 13.2与26.5 +/- 10.6%,p = 0.675),血清磷酸盐浓度(4.57 +/- 1.05与4.3 +/- 0.96 mg / dl,p = NS),完整的Pth(286 +/- 313与239 +/- 296 pg / ml,p = ns)。与COHORT B(9.18 +/- 0.58与8.9 +/- 0.51mg / dL相比,在群组中发现了较高的钙水平,分别在COHORT B(9.18 +/- 0.58mg / dl。在II期,在用SOH的6个月处理后,在血液学参数(HB:11.5 +/- 1.1至11.4 +/- 1.3g / dl,p = 0.4,血清铁蛋白水平:475 + / - 264至473 +/- 230 ng / ml,p = 0.951,TSAT:从26.5 +/- 16.7至26.6 +/-13.2%,p = 0.933)。在此期间,铁补充剂或促红细胞生成素剂量的给药也没有显着变化。结论:SOH是有效的PB,铁过载是一种有效的Pb,它的长期使用并不复杂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号